Encysive gets $195M offer from Pfizer

02/20/2008 | Houston Chronicle (tiered subscription model) · Forbes

Pfizer on Wednesday announced it intends to acquire Encysive Pharmaceuticals in a $195 million deal that would grant it rights to Thelin, Encysive's treatment for pulmonary arterial hypertension. Thelin is still struggling to obtain FDA approval, but Pfizer's expertise in the market for such treatments is likely to boost the chances of drug candidate to gain regulatory clearance, an analyst said.

View Full Article in:

Houston Chronicle (tiered subscription model) · Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN